1977-2005
The beginning
Scantox was originally founded in 1977, in the very same location which is today headquarters for the Scantox Group.
2005-2021
Different ownerships
During the years 2005 to 2021 the company site was under different ownerships, including LAB Research, CitoxLab and most recently Charles River.
2021
Scantox v.2.0
Since January 2021, the company has operated independently under the Scantox name with the Nordic equity fund Impilo as partner. With over 30 years of expertise built around the specialty area of preclinical research, the company is today a highly respected, trusted and valued partner for companies in medical and pharmaceutical industries worldwide. Furthermore, Scantox takes the worldwide lead in research based on the use of Göttingen Minipigs, and the Scantox experts are sought after speakers at conferences all over the world.
2022
An international journey of growth
With the acquisitions of the two Swedish CRO’s Timeline Bioresearch (Lund) and Adlego Biomedical (Solna), Scantox Sweden was added to the Scantox Group, taking the company to the leading position for Scandiavian preclinical CROs. Joining forces with the two highly specialized Swedish market players has added further capabilities to the portfolio of study types offered by Scantox, and marks an important milestone in the company’s journey of growth. Locally in Danmark, Scantox won the prize of Company of the Year 2022 in the Køge region where the Group Headquarters is located.
2023
Great Place To Work® – and the international growth journey continues
In April 2023 Scantox was proudly certified Great Place To Work®. The award is based entirely on what current employees say about their experience of working at Scantox. In August Scantox Sweden was expanded further with the acquisition of Q&Q Labs (Gothenburg), and in November Solural Pharma in Denmark was added to the Group.
2024
Scantox Neuro GmbH added to the Group
In April 2024 Scantox acquired QPS Neuropharmacology in Austria, adding a full host of neurological services to the portfolio of the Scantox Discovery unit. The Austrian subsidiary is now Scantox Neuro GmbH.
1977-2005 The beginning
Scantox was originally founded in 1977, in the very same location which is today headquarters for the Scantox Group.
2005-2021 Different ownerships
During the years 2005 to 2021 the company site was under different ownerships, including LAB Research, CitoxLab and most recently Charles River.
2021 Scantox v.2.0
Since January 2021, the company has operated independently under the Scantox name with the Nordic equity fund Impilo as partner. With over 30 years of expertise built around the specialty area of preclinical research, the company is today a highly respected, trusted and valued partner for companies in medical and pharmaceutical industries worldwide. Furthermore, Scantox takes the worldwide lead in research based on the use of Göttingen Minipigs, and the Scantox experts are sought after speakers at conferences all over the world.
2022 An international journey of growth
With the acquisitions of the two Swedish CRO’s Timeline Bioresearch (Lund) and Adlego Biomedical (Solna), Scantox Sweden was added to the Scantox Group, taking the company to the leading position for Scandiavian preclinical CROs. Joining forces with the two highly specialized Swedish market players has added further capabilities to the portfolio of study types offered by Scantox, and marks an important milestone in the company’s journey of growth. Locally in Danmark, Scantox won the prize of Company of the Year 2022 in the Køge region where the Group Headquarters is located.
2023 Great Place To Work® – and the international growth journey continues
In April 2023 Scantox was proudly certified Great Place To Work®. The award is based entirely on what current employees say about their experience of working at Scantox. In August Scantox Sweden was expanded further with the acquisition of Q&Q Labs (Gothenburg), and in November Solural Pharma in Denmark was added to the Group.
2024 Scantox Neuro GmbH added to the Group
In April 2024 Scantox acquired QPS Neuropharmacology in Austria, adding a full host of neurological services to the portfolio of the Scantox Discovery unit. The Austrian subsidiary is now Scantox Neuro GmbH.